Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

718 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators. Ribi K, et al. Among authors: goldhirsch a. Br J Cancer. 2020 Mar;122(7):1119. doi: 10.1038/s41416-019-0709-x. Br J Cancer. 2020. PMID: 31949268 Free PMC article.
Overhauling the breast cancer overview: are subsets subversive?
Coates A, Goldhirsch A, Gelber R; International Breast Cancer Study Group. Coates A, et al. Among authors: goldhirsch a. Lancet Oncol. 2002 Sep;3(9):525-6. doi: 10.1016/s1470-2045(02)00842-2. Lancet Oncol. 2002. PMID: 12217786 No abstract available.
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker?
Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA; International Breast Cancer Study Group. Trihia H, et al. Among authors: goldhirsch a. Cancer. 2003 Mar 1;97(5):1321-31. doi: 10.1002/cncr.11188. Cancer. 2003. PMID: 12599241 Free article.
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Spataro VJ, et al. Among authors: goldhirsch a. Cancer. 2003 Apr 1;97(7):1591-600. doi: 10.1002/cncr.11224. Cancer. 2003. PMID: 12655514 Free article.
Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam CM, Lindtner J, Fey MF, Senn HJ, Coates AS, Collins J, Goldhirsch A; International Breast Cancer Study Group. Crivellari D, et al. Among authors: goldhirsch a. J Clin Oncol. 2003 Dec 15;21(24):4517-23. doi: 10.1200/JCO.2003.03.559. J Clin Oncol. 2003. PMID: 14673038 Clinical Trial.
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG); Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD. International Breast Cancer Study Group (IBCSG), et al. Among authors: goldhirsch a. J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46. doi: 10.1093/jnci/djg119. J Natl Cancer Inst. 2003. PMID: 14679153 Clinical Trial.
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A. Thürlimann B, et al. Among authors: goldhirsch a. Breast Cancer Res Treat. 2004 Jun;85(3):247-54. doi: 10.1023/B:BREA.0000025420.78346.f9. Breast Cancer Res Treat. 2004. PMID: 15111763 Clinical Trial.
718 results